A new randomized trial tested whether combining three heart failure medications into one daily pill could outperform the current standard of prescribing separate drugs. In 212 adults with heart failure and reduced ejection fraction, the polypill — containing metoprolol, spironolactone, and empagliflozin — led to significantly greater improvement in heart pumping function after six months compared to enhanced usual care. Patients on the polypill also had 60% fewer hospitalizations or emergency department visits and were far more likely to actually take their medications. The trial enrolled a predominantly Black and underserved population, making the findings especially relevant for groups historically undertreated for heart failure. Results suggest that simplifying complex drug regimens into a single pill could meaningfully improve outcomes where adherence is the critical barrier.
